MDMB-BINACA
Chemical compound
From Wikipedia, the free encyclopedia
MDMB-BINACA (MDMB-BUTINACA) is an indazole-3-carboxamide based synthetic cannabinoid receptor agonist that has been sold as a designer drug, first identified in Sweden in May 2023. It has a similar chemical structure to potent cannabinoid agonists previously reported such as ADB-BUTINACA and MDMB-5'Br-BUTINACA, and is believed to have similar effects.[1]
| Identifiers | |
|---|---|
| |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C19H27N3O3 |
| Molar mass | 345.443 g·mol−1 |
| 3D model (JSmol) | |
| |
| |